Cyclin T2 (CCNT2) is the regulatory subunit of the cyclin-dependent kinase pair (CDK9/cyclin T) complex and also called positive transcription elongation factor B (P-TEFB).
Synonyms: Anti-CycT2 antibody produced in rabbit; Anti-Cyclin-T2 antibody produced in rabbit
Storage: -20C
Application: All Prestige Antibodies Powered by Atlas Antibodies are developed and validated by the Human Protein Atlas (HPA) project (www.proteinatlas.org)and as a result, are supported by the most extensive characterization in the industry. The Human Protein Atlas project can be subdivided into three efforts: Human Tissue Atlas, Cancer Atlas, and Human Cell Atlas. The antibodies that have been generated in support of the Tissue and Cancer Atlas projects have been tested by immunohistochemistry against hundreds of normal and disease tissues and through the recent efforts of the Human Cell Atlas project, many have been characterized by immunofluorescence to map the human proteome not only at the tissue level but now at the subcellular level. These images and the collection of this vast data set can be viewed on the Human Protein Atlas (HPA) site by clicking on the Image Gallery link. To view these protocols and other useful information about Prestige Antibodies and the HPA, visit sigma.com/prestige.
Biochem Physiol Actions: Cyclin T2 (CCNT2) is required as a cofactor and an activator. It has various roles in different cellular pathways such as transcriptional elongation, differentiation and apoptosis. It facilitates the transition from abortive to production elongation by phosphorylating the CTD (carboxy-terminal domain) of the large subunit of RNA polymerase II (RNAP II). Cdk9/cycT2 binds to pRb, involving residues 129-195 of cdk9, the region of cycT2 comprising amino acids 1-642 and the C-terminal region of the retinoblastoma protein (835-928). Cdk9 complexes phosphorylate the pRb region spanning amino acids 793-834.
Legal Information: Prestige Antibodies is a registered trademark of Sigma-Aldrich Co. LLC